- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 16-03-2026: Press Release
16-03-2026 | 08:15 pm
16-03-2026 | 08:15 pm
Zydus's Sentynl unit licensed Progerinin (SLC-D011) from PRG S&T, expanding its rare disease portfolio with a new investigational drug for Hutchinson-Gilford Progeria Syndrome. This strategic move strengthens Zydus's specialized offerings, with Phase 2A trial data anticipated soon. #Zydus #RareDisease
No comments yet. Be the first to comment!